GLOBAL PRODUCT PROTECTION

Global Product Protection

Counterfeiting, illegal diversion and theft of Abbott products globally pose threats to Abbott’s patients, consumers and the general public. We have four key strategies to address these threats:

  • Secure the Supply Chain:
    By analyzing the global supply chain for weak points, evaluating track and trace technologies and expanding the use of Exclusive Sourcing Agreements with contracted wholesalers, Abbott reduces the possibility of product diversion and/or theft.
  • Ensure Ability to Authenticate:
    By developing overt and covert security features on packaging, Abbott presents significant barriers to counterfeiters and facilitates authentication of its products, encouraging customer confidence.
  • Disrupt Criminal Organizations:
    By building relationships with local law enforcement and regulatory organizations, Abbott works to identify and dismantle criminal enterprises involved in counterfeiting, diversion and theft.
  • Build Global Momentum:
    By working with government, industry and not-for-profit organizations, Abbott pursues stricter sanctions for individuals and organizations involved in counterfeiting, diversion or theft.

Exclusive Sourcing Agreement (EAS)

The safety and integrity of Abbott products for the patients we serve is our highest priority. Abbott understands that the threat posed to public health and safety by counterfeit products is a very serious one. We regularly take action to keep counterfeit products out of the marketplace. Secondary market products are generally products purchased from any source other than from the original manufacturer and are commonly referred to as “secondary market,” “gray market” or “diverted” products. It is often through the secondary market that counterfeit, adulterated or improperly stored and handled products make their way into the distribution channel. When product comes from the secondary market, it is difficult to assure patients and healthcare professionals of the product's quality or safety or to provide product updates.

 

Through the exclusive sourcing initiative, Abbott is working to prevent the introduction of unsafe product into the United States. As of July 1, 2004, U.S.wholesale distribution of Abbott diabetes care products is permitted only through wholesalers/distributors that have agreed to source their entire product needs directly from Abbott. In select countries outside the U.S., Abbott has also implemented EASs and in many situations the EASs are silent to the specific Abbott division and simply say “Abbott”.

 

Letters required for signature for any wholesaler/distributor to purchase:

 

ESA for Abbott products (PDF)

List of U.S. wholesalers/distributors agreeing to these policies (PDF)

 

Standard Terms and Conditions:


Abbott Diabetes Care (Non-Retail) (PDF)

Abbott Diabetes Care (Retail) (PDF)

Abbott Diabetes Care (Wholesalers) (PDF)

 

 

Product Authentications

Abbott is committed to reducing the serious threat of counterfeit products. Included in this effort is the development of overt and covert product security features. One way Abbott provides information on these features to the marketplace is through product security flyers.

 

U.S. Product Security Fliers (overt security features on the packaging)

 

The following products have security fliers at www.abbvie.com/gpp.

 

Advicor®

Kaletra®

Lupron® (Also for Canada)

 

 

Niaspan® Bottles

Norvir®

Simcor®

 

 

Trilipix®

Ultane®

Zemplar®

 

 

Outside United States Product Security Fliers (overt security features on the packaging)

 

Dayamineral® (CACM only)

 

 

Niaspan® Blister Packs

 

Note: These Product Security Fliers highlight overt security features on the packaging. Although individual packaging configurations for the products may differ, the security features will remain the same.

The following products have security fliers at www.abbvie.com/gpp.

 

Aluvia™

Humira®

 

 

Kaletra®

Norvir®

 

 

Sevorane®

Zemplar®

 

All suspicions or leads on potential counterfeit, diverted or stolen Abbott product should be reported to Abbott’s Product Integrity team at 224-667-7970.

 

Note: All data reflects Abbott activities in 2012. Some content has been adjusted to remove data specific to AbbVie, which became a separate company on Jan. 1, 2013.

 

Related Links


true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?